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INTRODUCTION
Pregnancy is considered a diabetogenic state and starting it with overweight or obesity causes an 
increase in insulin resistance, which leads to the ß-cells ability depletion of insulin synthesis and 
secretion in sufficient quantities to manage the metabolic requirements triggered in pregnancy. 
is extra demand on maternal physiology is one of the causes that lead to the development of 
gestational diabetes mellitus (GDM).[1] As a matter of fact, the worldwide GDM prevalence shows a 
wide spectrum of prevalence, ranging from 5.4% in caucasian women to 11.9% in Asian and Pacific 
Islander women.[2] In Mexico, GDM complicates 12.9% of pregnancies[3] being a health challenge.
It is recognized that GDM and Type 2 diabetes mellitus (T2DM) share part of the pathophysiology 
and it has been shown that several genes of susceptibility to T2DM are associated with GDM.[4]
ABSTRACT
Objectives: Pancreatic duodenal homeobox factor-1 (PDX-1) and neurogenin-3 (NGN-3) are progenitor cell 
markers in the pancreas. e aim was to compare their serum levels in women with and without gestational 
diabetes mellitus (GDM).
Material and Methods: is prospective, cross-sectional study included two groups: (a) Women with normal 
gestation and (b) with GDM. PDX-1 and NGN-3 serum expression was determined by qRT-PCR. Student’s t-test 
or the Mann–Whitney U-test was used to contrast both groups and the Pearson or Spearman correlation was 
used. A multiple regression was done introducing body mass index and the relative expression of both genes as 
independent variables and glucose as dependent variable. Statistical significance was tested at P ≤ 0.05 level.
Results: irty-eight patients (mean age was of 29.00 ± 7.74 years) were included, 22 belonged to the normal 
pregnancies, and 16 to GDM. Using the ΔΔCt method, the expression fold change for PDX-1 was 0.458 and 
for NGN-3 it was 0.361. ere was a significant positive correlation between the expressions of both genes. e 
multiple regression was significant for both genes expression and glucose levels in case of having normal weight.
Conclusion: PDX-1 and NGN-3 low serum expression could be predictors of higher glucose levels in normal 
pregnancies. 
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ere are two pancreatic progenitor cell (stem cell) markers 
that stand out neurogenin-3 (NGN-3) and pancreatic duodenal 
homeobox factor-1 (PDX-1) which are also expressed in the 
adult pancreas.[5] Besides the corroborated function of PDX-1 as 
a necessary transcription factor for insulin, it also participates 
in the pancreas development and β-cell maturation.[6] On the 
other hand, it has been stated that pancreas islet progenitor 
cells are those NGN-3-positive cells in pancreases of embryonic 
or adult rats; thus, neurogenin-3 protein is considered an 
endocrine differentiation marker for β-cells.[7]
In general, glucose-stimulated insulin secretion is decreased 
after repeated exposure of β-cells to fatty acids, but this last 
high exposure diminishes the PDX-1 nuclear translocation and 
MafA (a β-cell-specific activator) expression, downregulates 
insulin expression, and induces apoptosis.[8,9] A compensatory 
response when β-cells decrease in adult animals is β-cell 
neogenesis activation. During the pancreas regeneration 
process, PDX-1 is reexpressed in proliferating cells of this 
gland[10,11] and it’s ducts,[12] and such cells gain a multipotent 
property to differentiate into any type of cell in the pancreas.
Within the pancreatic islets, Ngn3+ cells have been 
previously described as progenitor cells involving the ability 
to generate all endocrine cell lineages, including insulin-
producing β-cells.[13] e aim of this study was to compare 
the PDX-1 and NGN-3 serum expression levels in women 
with and without GDM.
MATERIAL AND METHODS
Setting
is was a prospective, clinical, cross-sectional study 
performed at the third level “Mónica Pretelini Sáenz” 
Maternal-Perinatal Hospital (HMPMPS), Health Institute of 
the State of Mexico (ISEM), Toluca, State of Mexico, Mexico, 
in the year 2018.
Patients
e invitation was made to all women who attended the 
Maternal Medicine Service of the HMPMP. e conditions 
required to exclude them from the study were autoimmune 
diseases, heart disease, nephropathy, liver disease, or any 
other chronic condition. If there were incomplete clinical 
files, they were discarded from the final analysis. Two groups 
were integrated: (a) Patients with normal gestation and 
(b) patients with GDM.
Sample
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Where, n0: necessary size of the sample, S: Standard 
deviation, d: Difference to find, Zα = 1.96, and Zβ: 0.482. 
Our measure to contrast was the relative units (RUs) of gene 
expression. Introducing 0.05 for the alpha risk, 0.2 for the 
beta risk, and a standard deviation (SD) of 4, a sample size 
of 16 subjects per group was necessary to detect an equal or 
greater difference at 4 RU.
Physical exploration
Body weight was measured with a digital scale (Tanita) with 
precision of 0.1 kg and the height was measured with accuracy 
of 0.1 cm with a Holtain stadiometer (Holtain Ltd., Crymych, 
United Kingdom). Body mass index (BMI) was calculated 
as usual, and other anthropometrics parameters were ideal 
weight based on the formula of Lorentz = ((Height (cm))-
100)-((Height (cm)-150)/2.5) and weight gain (kg) per month.
Laboratory
Blood samples were collected in Vacutainer tubes, 
after a fasting period of 8–12 h. Laboratory tests of 
albumin (mg/dL), creatinine (mg/dL), electrolytes 
(Na, Cl), glucose (mg/dL), total cholesterol (mg/dL), 
triglycerides (mg/dL), and aminotransferases (ALT and AST) 
were done at the Clinical Laboratory of the HMPMPS. e 
GDM diagnosis was based on the criteria of the American 
Diabetes Association (ADA) with an oral glucose load of 75 g 
with one or more values above the following ranges: 5.1 mmol/L 
(92 mg/dL) fasting, 10.0 mmol/L (180 mg/dL) at 1 h, and 8.5 
mmol/L (153 mg/dL) at 2 h (16). All studies were carried out 
following the recommendations of the International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC).
RNA extraction 
RNA was extracted from a peripheral blood sample using 
the using a Norgen’s Total RNA Purification Kit (Norgen 
Biotek Corp.) following the manufacturer’s protocol 
at the Laboratory of Genetics, Faculty of Medicine, 
Autonomous University of the State of Mexico (UAEMéx). 
e concentration and purity were quantified in a 
spectrophotometer (NanoDrop ND-100).
Real-time PCR expression
In the Research Laboratory of Ciprés Grupo Médico S.C. 
(CGM) using a real-time PCR PrimeQ (Techne, UK) 
equipment, the gene expression was determined with 
primers synthesized at the Synthesis and DNA Sequencing 
Unit of the National Autonomous University of Mexico 
(UNAM), Institute of Biotechnology (Cuernavaca, Morelos, 
Mexico). e QuantiNova SYBR Green RT-PCR Kit 
(Qiagen) was used with the following oligonucleotides: 
Global Journal of Medical, Pharmaceutical, and Biomedical Update • 2020 • 15(6) | 3
Santana, et al.: PDX-1 and NGN-3 in gestational diabetes
PDX-1 5’ GGATGAAGTCTACCAAAGCTCACGC 3’and 
3’ CCAGATCTTGATGTGTCTCTCGGTC 5’, NGN-3 5’ 
CAATCGAATGCACAACCTCA 3’ and 3’ GGGAGA CT 
GGGGAGTAGAGG 5’.[14] e reaction was done with a 
final volume of 20 μl, with primer concentrations of 200 
nM and RNA samples of 100 ng. Cycling was programmed 
as follows: Denaturation (95°C 15 s), alignment (95°C 15 s), 
extension (50°C 15 s), and melting curve (72°C 15 s) all for 
35 cycles. e fold changes of every gene were normalized 
against glyceraldehyde-3-phosphate dehydrogenase 
(GADPH) 5’CTTGGTATCGTGGAAGGACTC 3’ and 
3’GTAGAGGCAGGGATGATGTTCT 5’ and then compared 
with the controls through the 2−ΔΔCT method.
Statistical analysis
Continuous data were expressed as means ± SD. Once the 
Kolmogórov test has been performed for the normality 
of the variables, either the Student’s t-test or the Mann–
Whitney U-test was used to compare both groups. With 
the same criteria for normality, either Pearson or Spearman 
correlation was used among the genes’ relative expression 
and anthropometric variables. Point-biserial correlation was 
used to determine the correlation between the dichotomous 
variable GDM presence/absence and the relative 
quantification of any of both genes of interest. Furthermore, 
a multiple regression was done introducing BMI and the 
relative expression of both genes as independent variables 
and glucose as dependent variable. Statistical significance 
was tested at P ≤ 0.05 level using SPSS ver. 23.0 software 
(IBM Corp., Armonk, NY, USA).
Ethics
All participants gave their informed consent, and both 
the Research Committee and the Ethics on Research 
Committee of the HMPMPS approved the protocol 
(code: 2010-00-91). All procedures were performed in 
accordance with the Declaration of Helsinki (Fortaleza, 
Brazil, 2013) and the General Health Law in Mexico.
RESULTS
Data were obtained from 38 patients of whom 22 belonged 
to the control group and 16 to the experimental group. 
e mean age was of 29.00 ± 7.74 years. e general 
characteristics of the patients are shown in Table  1. e 
distribution of age, height, BMI, and cholesterol was normal, 
for the rest of the variables, a free distribution was identified 
and the appropriate statistical analysis was applied.
About family history, in the GDM group, three women 
mentioned a first degree relative that suffered the same 
metabolic complication, while in the control group, only one 
patient had known a similar case in her family.
Women with GDM had significantly higher serum glucose 
concentrations than patients in the control group and 100% 
of them had concentrations above 100 mg/dl (or 5.5 mmol/L) 
while only two patients in the control group had high 
concentrations. Cholesterol and triglycerides concentrations 
were within the normal parameters and there were no 
significant differences between the groups.
Taking into account the ideal weight (54.93 ± 4.95 kg) 
of the whole population, the average increase in weight 
Table 1: Basal characteristics of the patients.
Variable General Control group (n=22) Mean±SD GDM (n=16) Mean±SD P-value
Age (years) 29.0±1.2 27.3±1.5 31.2±2.1 0.249a
BMI (kg/m2) 26.2±0.3 26.8±0.4 25.5±0.6 0.760a
Pregestational BMI (kg/m2) 26.8±5.0 29.3±5.6 24.4±3.5 0.094
Albumin (mg/dL) 2.3±0.1 2.3±0.1 2.2±0.1 0.243a
ALT (mg/dL) 44.0±8.5 39.4±0.9 50.4±18.8 0.895
AST (mg/dL) 34.4±3.3 36.7±4.2 31.1±5.2 0.234
Cholesterol (mg/dL) 182.1±6.1 182.4±8.6 181.8±9.1 1.00
Creatinine (mg/dL) 0.79±0.1 0.87±0.1 0.7±0.6 0.781
Gestational age (weeks) 32.9±5.0 34.5±3.0 30.7±6.5 0.190
Glucose (mg/dL) 133.9±13.0 86.5±2.1 199.2±22.3 0.001
Hemoglobin A1C (%) 6.5±1.3 5.9±1.4 7.1±1.1 0.04
Triglycerides (mg/dL) 243.8±14.9 241.5±14.8 247.0±29.7 0.115a
Urea (mg/dL) 28.6±3.4 33.2±5.5 22.2±2.4 0.285
K (mg/dL) 3.8±0.1 3.9±0.1 3.7±0.1 0.162
Na (mg/dL) 134.7±1.1 135.0±1.3 134.2±2.0 0.715
PDX-1 (RU) 3.6±1.5 5.9±2.7 1.3±0.4 0.246
NGN-3 (RU) 1016±373.5 1556.1±595.1 477.6±152.0 0.455
aStudent’s t-test. ALT: Alanine transaminase, AST: Aspartate transaminase, BMI: Body mass index, PDX-1: Pancreatic duodenal homeobox factor-1,  
NGN-3: Neurogenin-3, RU: Relative units
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Table 3: Spearman correlation between the variables and each gene.
Variable Gene Correlation
R2 P
Age (years) PDX-1 0.076 0.648
NGN-3 0.052 0.758
BMI (kg/m2) PDX-1 0.061 0.716
NGN-3 0.021 0.898
Glucose (mg/dL) PDX-1 –0.072 0.666
NGN-3 –0.221 0.182
Cholesterol (mg/dL) PDX-1 –0.154 0.356
NGN-3 –0.154 0.357
Triglycerides (mg/dL) PDX-1 –0.16 0.339
NGN-3 –0.134 0.421
ALT (mg/dL) PDX-1 –0.254 0.124
NGN-3 –0.064 0.704
Albumin (mg/dL) PDX-1 –0.157 0.346
NGN-3 –0.049 0.771
AST (mg/dL) PDX-1 –0.21 0.206
NGN-3 –0.094 0.573
Creatinine (mg/dL) PDX-1 –0.066 0.692
NGN-3 –0.058 0.731
K (mg/dL) PDX-1 –0.166 0.319
NGN-3 –0.058 0.731
Na (mg/dL) PDX-1 0.188 0.257
NGN-3 –0.058 0.731
Urea (mg/dL) PDX-1 –0.112 0.505
NGN-3 –0.082 0.624
PDX-1 (RU) NGN-3 0.751 0.001
ALT: Alanine transaminase, AST: Aspartate transaminase, BMI: Body 
mass index, PDX-1: Pancreatic duodenal homeobox factor-1,  
NGN-3: Neurogenin-3, RU: Relative unit
Table 2: BMI by group.






Normal 5 (22.7) 4 (25.0) 9 (23.7)
Overweight 8 (36.4) 8 (50.0) 16 (42.1)
Obesity Grade 1 6 (27.3) 3 (18.8) 9 (23.7)
Obesity Grade 2 0 (0.0) 1 (6.3) 1 (2.6)
Morbid obesity 313.6 0 (0.0) 3 (7.9)
Total (22) 16 38
gain was of 18.47 ± 12.96 kg. Furthermore, for weight and 
height, no significant differences were observed, in fact, the 
weight gain per month was similar in both groups 1.56 ± 
0.07 kg in the GDM group and 1.60 ± 0.08 kg in the normal 
gestation group, however, 50% of the GDM patients had 
a BMI classified as overweight and only 36% of the control 
patients were identified within the same category. As far as 
obesity cases, the control group had more cases with Grade 1 
(27.3%) and morbid obesity (13.6%) compared to the GDM 
group which had no cases of morbid obesity and only 18.8% 
of Grade 1 cases [Table 2].
e point-biserial correlation between the GDM presence/
absence and the RU of NGN3 showed an r of –0.24311 
(P = 0.14136), the same test between the GDM presence/absence 
and the RU of NGN3 showed an r of –0.23264 (P = 0.15986). 
Using the ΔΔCt method, the expression fold change for 
PDX-1 was 0.458 and for NGN-3, it was 0.361. In the Spearman 
correlation analysis, there were no significant results between 
the clinical variables and the gene expression in any group, 
but there was a statistically significant correlation between the 
expression values of both genes in both groups [Table 3].
At last, the multiple regression per BMI classification, for 
glucose, showed that the model constructed with both PDX-
1 and NGN-3 was significant in women with normal weight 
[Table 4].
DISCUSSION 
Until now, hundreds of genetic variations related with 
T2DM or glucose/insulin have been identified by genome-
wide association studies.[15,16] Most of these genes perform 
biological processes which affect the pancreatic β-cell 
number or function.[17] It has been known that overweight 
and obesity are factors linked to various types of diabetes 
and here we found that the majority (75.1%) of the GDM 
patients had a BMI corresponding to overweight, Grade 1 
obesity or Grade 2 obesity; interestingly, the control group 
had a higher percentage of Grade 1 obesity and morbid 
obesity and the combined percentage with overweight cases 
was slightly higher overall (77.3%), this could be explained 
by the treatment of GDM patients since they have to follow 
a stricter dietetic plan to keep their glucose levels in good 
targets, whereas the control group patients only followed 
the general dietetic recommendations for pregnancy, it is 
also possible that the weight estimation required additional 
corrections for the expected changes of pregnancy and BMI 
does not take into account the adipose tissue distribution. 
With these findings, it is once again clear that GDM and 
T2DM are multifactorial diseases, and the genetic factors 
must be taken into account to understand them.
Following the previously mentioned arguments, interactome 
studies of GDM are still in their phase of increase [Table 5]. 
e identification of additional genetic markers that could 
explain the differences in the susceptibility to GDM would 
represent a crucial point to establish a strategy for prevention, 
early diagnosis, and treatment of this condition.
In the present study, although it was not reached a statistical 
difference, both PDX-1 and NGN-3 showed a tendency to 
be underexpressed in patients with GDM compared with 
patients who had a normal pregnancy, these results are in 
line with the findings of Wang et al. (2018) where PDX-1 was 
underexpressed in the fetal side of placental tissue of patients 
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with GDM, and they also reported PGC-1α mutilation.[18] 
Interestingly, the fact that in the group of pregnant women 
with normal weight, the serum levels of both genes showed a 
significant value in the regression for glucose could be a tool 
to predict a future β-cell failure.
NGN-3 studies in humans are rare and even rarer during 
pregnancy because they would require a pancreas sample, 
which is not a viable procedure for diagnosis during 
pregnancy. e alternative approach proposed here is to use 
blood samples to perform the mRNA quantification and our 
findings suggest that it is possible to obtain similar results to 
those previously reported for the NGN-3 protein that is present 
in adult human pancreas from surgical and cadaveric tissue. In 
fact, in murine models for pregnancy and diabetes, the results 
suggest a similar expression decrement but the mice usually 
go through experimental manipulation to achieve the NGN-3 
expression and the systemic response of such manipulation in 
humans would most likely be different.[19]
e potential NGN-3 expression manipulation in non-β-cells 
could greatly improve the treatment for T2DM and GDM 
but the current evidence in vivo is not enough to warrant 
beneficial results without negative side effects, for this study, 
we limit our scope to use these molecular tests as potential 
diagnosis tools that ensure an accurate treatment throughout 
pregnancy, both genes had a similar expression behavior and 
the statistical correlation between their expression values 
suggests that they might share more pathways than we 
currently know, more interactomes studies are necessary to 
fully understand this possible relation.
Some final remarks deserve to be mentioned. It is a bit 
risky to propose a specific stage of the pregnancy to request 
the quantification of the relative expression of NGN-3 and 
PDX-1, but pretending to have enough time for a prevention 
intervention, it could be suggested to measure them after the 
20th week of gestation. 
Table 5: Review of genes related to GDM.
Genes Reference Sample Findings
IRS-1 and PPARγ Cheng et al. (2017). Fasting mimicking diet 
promotes ngn3-driven β-cell regeneration 
to reverse diabetes
Human Decreased expression of IRS-1 (might reduce insulin 
suppression of lipolysis) and PPARγ in GDM patients 
compared with non-pregnant controls
PGC-1α and PDX1 Wang et al. (2018). Altered expression of 
PGC-1α and PDX1 and their methylation 
status are associated with fetal glucose 
metabolism in gestational diabetes mellitus
Human Lower levels of PGC-1α and PDX1 in the GDM group 
compared with the non GDM group as well as higher 
methylation levels of the PGC-1α gene on the GDM 
group but lower on PGC-1α and PDX1 mRNA
NGN-3 Toselli et al. (2014). Contribution of a 
non-β-cell source to β-cell mass during 
pregnancy
Mice Decreased expression of Ngn3 in pancreatic islets 
during pregnancy
GCK Zubkova et al. (2019). High frequency of 
pathogenic and rare sequence variants 
in diabetes-related genes among Russian 
patients with diabetes in pregnancy
Human 28 pathogenic variations of which the majority 
occurred in the GCK gene
ACLY Mac-Marcjanek et al. (2018). Expression 
profile of diabetes-related genes associated 
with leukocyte sirtuin 1 overexpression in 
gestational diabetes
Human In groups with GDM and over expression of SIRT1, 





Khan et al. (2019). Genetic confirmation 
of T2DM meta-analysis variants studied in 
gestational diabetes mellitus in an Indian 
population
Human Positive association of GDM with the polymorphisms 
Multiple SNP’s 
of TCF7L2 and 
KCNQ1
Huerta-Chagoya et al. (2015). Genetic 
determinants for gestational diabetes 
mellitus and related metabolic traits in 
Mexican women
Human Strong association of the TCF7L2 and KCNQ1 
variants with risk of developing GDM and higher 
frequency of family history of diabetes in cases, 
compared to controls
Table 4: Multiple regression per BMI classification for glucose.
BMI category Model Standardized coefficient
Beta P-value
Normal 1 (Constant) 0.067
NGN-3 –3.130 0.002
PDX-1 3.348 0.001
Overweight/obesity 1 (Constant) 0.000
NGN-3 –0.407 0.432
PDX-1 0.170 0.742
BMI: Body mass index, PDX-1: Pancreatic duodenal homeobox factor-1, 
NGN-3: Neurogenin-3
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e association of PDX-1 and NGN-3 with the GDM severity 
should be a complementary analysis but was beyond the 
scope of this initial approach. To set up the cutoff value for 
these genes as predictors of high glucose levels, it will be 
necessary to perform a longitudinal study. However, with the 
information obtained in this initial study, there is a possibility 
that these genes could indeed have a place in clinical practice, 
as predictors for a high glucose value during pregnancy, 
although much remains to be done and demonstrated.
If the correlation between the decrease of PDX1 and 
NGN-3 with the condition of hyperglycemia and the 
appearance of GDM is corroborated, one could be witnessing 
the same phenomenon that occurs with patients with T2DM, 
in whom the decrease or loss of these transcription factors 
has been demonstrated with the chronicity of the disease 
(between 10 and 15). is highly accelerated process of 
β-cell loss in pregnancy can be visualized as an accelerated 
burnout state, potentiated by the appearance of insulin 
counterregulatory hormones in gestation: Cortisol (serum 
level doubles in pregnancy), placental lactogen (main increase 
in the second half of pregnancy), estrogens, and progesterone.
A limitation of the study is the variability in the evolution 
of BMI during pregnancy, however, it is a simple and 
practical tool that allows us to monitor when it comes to 
the care of thousands of patients as it is our case. e same 
variable has previously been considered for regressions 
with other parameters with useful results.[20] Of course, to 
carry out a more precise study to determine the association 
between gestational weight gain and the genes of interest, 
ideally, it would be necessary to quantify the increase in 
visceral adipose tissue. Finally, the next steps in our line of 
research will be the construction of the NGN-3 and PDX1 
recombinant proteins to expand the analytical options to 
corroborate our hypothesis.
CONCLUSION
In normal weight pregnant women, PDX-1 and NGN-3 serum 
levels might be related with the glucose serum concentration.
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